EMMAA dashboard

Model Info

Item	Details
Last Updated	2019-10-23-17-10-02
Network on Ndex	ef58f76d-f6a2-11e8-aaa6-0ac135e8bacf

Statement Types Distribution

Top 10 Agents

Most Supported Statements

Statement	Evidence Count
TP53 binds TP53.	571
ANG translocates to the nucleus.	307
MAX is phosphorylated.	259
EED binds EZH2.	242
ASXL1 is phosphorylated.	212
RUNX1 binds CBFB.	147
FLT3 phosphorylates itself.	143
KRAS is farnesylated.	128
IDH1 binds IDH1.	116
NPM1 is phosphorylated on T199.	99

Number of Statements over Time

New Added Statements

No new statements were added

Percentage of Tests Passed

Passed and Applied Tests

New Applied Tests

No new tests were applied

New Passed Tests

No new tests were passed

All Test Results

Test	PySB	PyBEL	Signed Graph	Unsigned Graph
AGT activates EGFR.
Kinase-active FLT3 activates AKT.
IL6 activates AKT.
IL6 activates CBL.
IL6 activates KRAS.
TP53 bound to TP53, TP53, and TP53 activates TP53.
Resveratrol activates TP53.
TP53-R156P decreases the amount of TP53.
TP53-R175L decreases the amount of TP53.
TP53-M246I decreases the amount of TP53.
TP53-P250L decreases the amount of TP53.
Resveratrol decreases the amount of IGF1R.
AGT increases the amount of CDKN1A.
AGT increases the amount of IGF1R.
AGT increases the amount of TP53.
KRAS increases the amount of CDKN1A.
TP53 phosphorylated on S15 increases the amount of TP53.
Transcriptionally active TP53 increases the amount of CDKN1A.
Bortezomib increases the amount of RUNX1.
Celecoxib increases the amount of GZMB.
Cisplatin increases the amount of CDKN1A.
Cisplatin increases the amount of TP53.
Resveratrol increases the amount of TP53.
CDC42 inhibits TP53.
Catalytically active MDM2 inhibits TP53.
Transcriptionally active TP53 inhibits AKT.
Cisplatin inhibits GCLM.
Resveratrol inhibits AKT.
Resveratrol leads to the phosphorylation of TP53 on serine.
MDM2 bound to RPL23 activates TP53.
TP53 bound to TP53BP2 activates TP53.
IL6 increases the amount of IGF1R bound to IL6R.
RUNX1 bound to SUV39H1 inhibits RUNX1.
WT1 bound to WTIP inhibits WT1.
AGT activates IGF1R.
IL6 activates ERK.
Kinase-active KIT activates AKT.
Phosphatase-active PTPN11 activates EGFR.
Phosphatase-active PTPN11 activates ERK.
PTPN11 activates AKT.
Lipopolysaccharide activates AKT.
Lipopolysaccharide activates ERK.
Resveratrol activates ERK.
HNRNPK decreases the amount of CDKN1A.
IL6 decreases the amount of AKT.
MDM2 decreases the amount of CDKN1A.
Bortezomib decreases the amount of BCL2.
Erlotinib decreases the amount of FABP4.
Resveratrol decreases the amount of BCL2.
Resveratrol decreases the amount of IL1B.
Staurosporine decreases the amount of EGFR.
Catalytically active CBL increases the amount of EGFR.
CDKN1A increases the amount of CDKN1A.
Transcriptionally active HOXA9 increases the amount of EGFR.
Transcriptionally active HOXA9 increases the amount of RAP1B.
IL6 increases the amount of EGFR.
Catalytically active MDM2 increases the amount of TP53.
MDM2 increases the amount of TP53.
Transcriptionally active Notch increases the amount of CDKN1A.
Transcriptionally active Notch increases the amount of TP53.
Lipopolysaccharide increases the amount of BCL2.
Lipopolysaccharide increases the amount of IL1B.
Lipopolysaccharide increases the amount of RAP1B.
Lipopolysaccharide increases the amount of SLPI.
Catalytically active CBL inhibits EGFR.
CDKN1A inhibits MAP3K5.
IL6 inhibits FOXO1.
Phosphatase-active PTPN11 inhibits JAK.
Erlotinib inhibits ERK.
Resveratrol inhibits ERK.
IL6 leads to the phosphorylation of STAT3.
Transcriptionally active TP53 leads to the phosphorylation of STAT3.
Catalytically active DRD2 leads to the phosphorylation of EGFR on Y869.
IL6 leads to the phosphorylation of FOXO1.
Kinase-active KIT leads to the phosphorylation of JAK2.
MDM2 leads to the phosphorylation of TP53 on S15.
TP53 leads to the phosphorylation of IGF1R on Y1161.
Erlotinib leads to the phosphorylation of AKT.
Erlotinib leads to the phosphorylation of EGFR.
Lipopolysaccharide leads to the phosphorylation of AKT on S473.
Lipopolysaccharide leads to the phosphorylation of AKT on serine.
AGT bound to AGTR1 activates ERK.
ANG activates cell differentiation.
HOXA9 activates angiogenesis.
KIT phosphorylated on Y721 activates AKT.
Kinase-active KIT activates cell differentiation.
GTP-bound active KRAS activates angiogenesis.
Transcriptionally active MYC activates cell cycle.
Transcriptionally active Notch activates cell differentiation.
WNT5A activates cell differentiation.
WT1 activates cell cycle.
CBL bound to EGFR decreases the amount of EGFR.
GTP-bound active KRAS increases the amount of KRAS bound to RASSF2.
Kinase-active ATM inhibits cell cycle.
CCL21 inhibits angiogenesis.
CDKN1A inhibits cell cycle.
CDKN1A bound to MAP3K5 inhibits MAP3K5.
Transcriptionally active TP53 inhibits cell cycle.
TP53 inhibits cell cycle.
TP53 inhibits translation.
Erlotinib inhibits cell cycle.
APEX1 bound to TXN activates APEX1.
Catalytically active ARHGDIA activates ESR1.
Transcriptionally active AR activates EP300.
Kinase-active BRAF activates ERK.
CD70 activates MEK.
GTP-bound active CDC42 activates STAT3.

IndraLab

EMMAA Dashboard Queries

Model Info

Statement Types Distribution

Top 10 Agents

Most Supported Statements

Number of Statements over Time

New Added Statements

Percentage of Tests Passed

Passed and Applied Tests

New Applied Tests

New Passed Tests

All Test Results